Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease
We look forward to collaborating with FDA and utilizing the benefits associated with Fast Track designation to make this important therapy available for patients with IFALD.
- We look forward to collaborating with FDA and utilizing the benefits associated with Fast Track designation to make this important therapy available for patients with IFALD.
- Programs with Fast Track designation may benefit from early and frequent interactions with the FDA over the course of drug development.
- IV Choline Chloride has been granted Orphan Drug Designation for the treatment of IFALD and prevention of choline deficiency in PN patients.
- IV Choline Chloride has also been granted Fast Track Designation for the treatment of IFALD.